NeuroPace Inc (NAS:NPCE)

Q1 2025 Neuropace Inc Earnings Call Transcript

May 13, 2025 / 08:30 PM GMT

Release Date Price: $12.95 (-3.14%)

Transcript 10-Q8-K

Key Points

Positve

NeuroPace Inc (NPCE) reported a strong first quarter with total revenue of $22.5 million, marking a 24% increase compared to the previous year.
The company's RNS sales grew by 26%, or 29% when excluding the impact of Nautilus study implants in Q1 2024.
NeuroPace Inc (NPCE) completed a $75 million follow-on equity financing, enhancing its financial position.
The company presented compelling three-year effectiveness data from its post-approval study, showing an 82% median reduction in seizures for adults treated with brain-responsive stimulation.
Gross margin improved to 77% in the first quarter of 2025, up from 73.6% in the same period of 2024, driven by improved manufacturing efficiency and higher production volumes.

Negative

Research and development expenses increased to $7.4 million in Q1 2025 from $5.8 million in the same period of 2024, due to increased personnel and program expenses.
The company announced the termination of its distribution of SEEG products, which could impact future revenue streams.
Despite revenue growth, NeuroPace Inc (NPCE) reported a net loss of $6.6 million for the first quarter of 2025.
Operating expenses rose to $22.5 million in Q1 2025, representing an 8% increase compared to the prior year.
The company anticipates potential fluctuations in gross margin due to the proportion of SEEG revenue and other factors, which could impact financial stability.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

NPCE.OQ - Neuropace Inc
Q1 2025 Neuropace Inc Earnings Call
May 13, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
.

Greetings and welcome to the neuro pace 1st quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow a formal presentation. If anyone should require operator assistance, please press 0 on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce Jeremy Pfeffer of Life Sci Advisors. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Good afternoon.

Thank you for joining us for Neuropace's first quarter 2025 Financial and operating

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.